Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 5,198 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Tumor Clear all
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)

NCT04200534
View directory record Official record
Conditions
Smoking, Lung Cancer
Interventions
Best Practice, Nicotine Patch, Quality-of-Life Assessment, Questionnaire Administration, Tobacco Cessation Counseling
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 77 Years
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
3
States / cities
Galveston, Texas • Houston, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 22, 2026, 10:13 PM EDT
Withdrawn Early Phase 1 Interventional

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

NCT04870034
View directory record Official record
Conditions
Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
Interventions
Binimetinib, Palbociclib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 22, 2026, 10:13 PM EDT
Active, not recruiting No phase listed Observational

Using e-Nose Technology to Identify Early Lung Cancer

NCT04734145
View directory record Official record
Conditions
Lung; Node, Lung Cancer
Interventions
Breathprinting test
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

NCT02899195
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma
Interventions
Durvalumab
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Not applicable Interventional

Evaluation of a Patient 'nudge' on Engagement in Lung Cancer Screening

NCT06474611
View directory record Official record
Conditions
Lung Cancer
Interventions
Patient nudge
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 80 Years
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT05241834
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Interventions
LOXO-260
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00006929
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
suramin, carboplatin, paclitaxel, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 22, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan in People With Mesothelioma

NCT06477419
View directory record Official record
Conditions
Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
Interventions
Sacituzumab govitecan-hziy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

NCT01827267
View directory record Official record
Conditions
HER2-mutant Non-Small Cell Lung Cancer
Interventions
neratinib, temsirolimus
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
15
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

NCT00633529
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
IMO-2055
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 22, 2026, 10:13 PM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 22, 2026, 10:13 PM EDT
Recruiting Not applicable Interventional

Prediction Augmented Screening Initiative

NCT06538636
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Screening
Interventions
PCP-Facing Tools, LCS team population management tools
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 80 Years
Enrollment
23,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Bedford, Massachusetts • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

NCT02314364
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1)
Interventions
SBRT with protons or photons
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 22, 2026, 10:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

NCT03831932
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Osimertinib, Positron Emission Tomography, Telaglenastat Hydrochloride, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Coral Gables, Florida • Deerfield Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Survival Prolongation by Rationale Innovative Genomics

NCT03386929
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Interventions
Avelumab, Axitinib, Palbociclib
Drug
Lead sponsor
Worldwide Innovative Network Association
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 22, 2026, 10:13 PM EDT
Terminated Not applicable Interventional

Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors

NCT05609331
View directory record Official record
Conditions
Lung Cancer
Interventions
Simulated Online Adaptive Planning, Stereotactic MRI-guided adaptive radiotherapy-SMART
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 22, 2026, 10:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

NCT06088771
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Dupilumab, Cemiplimab
Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03909334
View directory record Official record
Conditions
Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
Interventions
Osimertinib, Ramucirumab
Drug
Lead sponsor
Xiuning Le
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Recruiting Phase 3 Interventional

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245
View directory record Official record
Conditions
Patients With Non-Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, NGS HLAA2 assay
Drug · Device
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Beverly Hills, California • Encino, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Cancer Biomarkers and Screening

NCT00301119
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
3,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

NCT00387465
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine 30mg/m2, Entinostat, Azacitidine 40mg/m2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 22, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02289833
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Trastuzumab Emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 22, 2026, 10:13 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

NCT02706626
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
brigatinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 22, 2026, 10:13 PM EDT